LAVA Therapeutics N.V. articles

Bispecific antibodies that target tumors by engaging innate-like T cell subsets with inherent antitumor activity

Bispecific antibodies that target tumors by engaging innate-like T cell subsets with inherent antitumor activity

• CD1d can be expressed by several hematologic malignancies
• Bispecific Vγ9Vδ2-T cell engager
• Unique ab

Purpose:Although considerable progress has been made withautologous T cell–based therapy in B-cell malignancies, appli-cation in chronic lymphocytic leukemia (CLL) lags behind dueto disappointing response rates as well as substantial toxicitythat is of particular concern in the elderly CLL population.Vg9Vd2-T cells form a conserved T-cell subset with strongintrinsic immunotherapeutic potential, largely because of theircapacity to be triggered by phosphoantigens that can